Abstract
The introduction of recombinant human thyrotropin (thyroid-stimulating hormone or TSH) (rhTSH; thyrotropin alfa; Thyrogen®, Genzyme Corporation, Cambridge, MA) has permitted the development of new diagnostic and treatment strategies for patients with a variety of thyroid diseases (1,2). Originally introduced as a diagnostic adjunct in the follow-up of patients with thyroid carcinoma, broader interest has led to testing of the hormone to facilitate radioiodine therapy for benign, malignant, and ectopic thyroid neoplasms. Optimal utilization of this new mode of hormone therapy requires careful consideration of the normal physiology of TSH action and the benefits and limitations of the agent.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
